Skip to main content

MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum.

Publication ,  Journal Article
Lew, CO; Zhou, L; Mazurowski, MA; Doraiswamy, PM; Petrella, JR; Alzheimer's Disease Neuroimaging Initiative
Published in: Radiology
October 2023

Background PET can be used for amyloid-tau-neurodegeneration (ATN) classification in Alzheimer disease, but incurs considerable cost and exposure to ionizing radiation. MRI currently has limited use in characterizing ATN status. Deep learning techniques can detect complex patterns in MRI data and have potential for noninvasive characterization of ATN status. Purpose To use deep learning to predict PET-determined ATN biomarker status using MRI and readily available diagnostic data. Materials and Methods MRI and PET data were retrospectively collected from the Alzheimer's Disease Imaging Initiative. PET scans were paired with MRI scans acquired within 30 days, from August 2005 to September 2020. Pairs were randomly split into subsets as follows: 70% for training, 10% for validation, and 20% for final testing. A bimodal Gaussian mixture model was used to threshold PET scans into positive and negative labels. MRI data were fed into a convolutional neural network to generate imaging features. These features were combined in a logistic regression model with patient demographics, APOE gene status, cognitive scores, hippocampal volumes, and clinical diagnoses to classify each ATN biomarker component as positive or negative. Area under the receiver operating characteristic curve (AUC) analysis was used for model evaluation. Feature importance was derived from model coefficients and gradients. Results There were 2099 amyloid (mean patient age, 75 years ± 10 [SD]; 1110 male), 557 tau (mean patient age, 75 years ± 7; 280 male), and 2768 FDG PET (mean patient age, 75 years ± 7; 1645 male) and MRI pairs. Model AUCs for the test set were as follows: amyloid, 0.79 (95% CI: 0.74, 0.83); tau, 0.73 (95% CI: 0.58, 0.86); and neurodegeneration, 0.86 (95% CI: 0.83, 0.89). Within the networks, high gradients were present in key temporal, parietal, frontal, and occipital cortical regions. Model coefficients for cognitive scores, hippocampal volumes, and APOE status were highest. Conclusion A deep learning algorithm predicted each component of PET-determined ATN status with acceptable to excellent efficacy using MRI and other available diagnostic data. © RSNA, 2023 Supplemental material is available for this article.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Radiology

DOI

EISSN

1527-1315

Publication Date

October 2023

Volume

309

Issue

1

Start / End Page

e222441

Location

United States

Related Subject Headings

  • tau Proteins
  • Retrospective Studies
  • Positron-Emission Tomography
  • Nuclear Medicine & Medical Imaging
  • Male
  • Magnetic Resonance Imaging
  • Humans
  • Female
  • Deep Learning
  • Cognitive Dysfunction
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lew, C. O., Zhou, L., Mazurowski, M. A., Doraiswamy, P. M., Petrella, J. R., & Alzheimer’s Disease Neuroimaging Initiative. (2023). MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum. Radiology, 309(1), e222441. https://doi.org/10.1148/radiol.222441
Lew, Christopher O., Longfei Zhou, Maciej A. Mazurowski, P Murali Doraiswamy, Jeffrey R. Petrella, and Alzheimer’s Disease Neuroimaging Initiative. “MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum.Radiology 309, no. 1 (October 2023): e222441. https://doi.org/10.1148/radiol.222441.
Lew CO, Zhou L, Mazurowski MA, Doraiswamy PM, Petrella JR, Alzheimer’s Disease Neuroimaging Initiative. MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum. Radiology. 2023 Oct;309(1):e222441.
Lew, Christopher O., et al. “MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum.Radiology, vol. 309, no. 1, Oct. 2023, p. e222441. Pubmed, doi:10.1148/radiol.222441.
Lew CO, Zhou L, Mazurowski MA, Doraiswamy PM, Petrella JR, Alzheimer’s Disease Neuroimaging Initiative. MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum. Radiology. 2023 Oct;309(1):e222441.

Published In

Radiology

DOI

EISSN

1527-1315

Publication Date

October 2023

Volume

309

Issue

1

Start / End Page

e222441

Location

United States

Related Subject Headings

  • tau Proteins
  • Retrospective Studies
  • Positron-Emission Tomography
  • Nuclear Medicine & Medical Imaging
  • Male
  • Magnetic Resonance Imaging
  • Humans
  • Female
  • Deep Learning
  • Cognitive Dysfunction